Expanded IMPACT For GSK Respiratory Business From New Trelegy Data

 
• By Eleanor Malone

Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta and Anoro Ellipta support the product's ability to reduce exacerbations in more severe COPD. However, the benefit of IMPACT in expanding GSK's respiratory sales may be limited given pricing pressures and the make-up of GSK's current portfolio.

Thumbs up
Positive IMPACT for GSK's triple therapy Trelegy Ellipta • Source: Shutterstock

Positive headline data comparing the once-daily, single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD) Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) with two products containing two of its three active ingredients have provided another boon to GlaxoSmithKline PLC and partner Innoviva Inc., following US approval and a positive opinion from EU regulators.

Data from the IMPACT trial complement those from the FULFIL trial comparing Trelegy Ellipta to AstraZeneca's Symbicort TurbuHaler (budesonide/formoterol fumarate), which was used to support the US and EU filings....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D